Form 4: Agios Pharmaceuticals CFO Cecilia Jones Reports Stock Transactions

Cecilia Jones, CFO of Agios Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• Cecilia Jones, the Chief Financial Officer of Agios Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On September 26, 2024, Jones acquired 7,473 shares of common stock through the vesting of restricted stock units.
• Also on September 26, 2024, Jones sold 2,542 shares of common stock at a price of $49.03 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• These transactions were executed according to a pre-arranged plan under Rule 10b5-1(c).
• Following these transactions, Jones directly owns 20,158 shares of common stock and 7,472 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1(c) trading plan, indicating no insider information was used.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders across all publicly traded companies, including Agios's competitors.
• The use of a 10b5-1 trading plan is a common method for insiders to manage their stock transactions while avoiding accusations of insider trading, aligning with industry best practices.

Key Dates